Risk analysis of lurasidone in patients with schizophrenia and bipolar depression.

CONCLUSION: In conclusion, Marketing Authorization Holder (MAH) and Regulatory Authorities (RA) should monitor these adverse drug reactions. PMID: 32124704 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/32124704?dopt=Abstract

Source: CNS and Neurological Disorders Drug Targets - March 2, 2020 Category: Drugs & Pharmacology Authors: Modugula H, Kumar A Tags: CNS Neurol Disord Drug Targets Source Type: research